Infarct Volume Is a Pivotal Biomarker After Intra-Arterial Stroke Therapy
- 1 May 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 43 (5), 1323-1330
- https://doi.org/10.1161/strokeaha.111.639401
Abstract
Background and Purpose—: Pretreatment infarct volume appears to predict clinical outcome after intra-arterial therapy. To confirm the importance of infarct size in patients undergoing intra-arterial therapy, we sought to characterize the relationship between final infarct volume (FIV) and long-term functional outcome in a prospective cohort of endovascularly treated patients. Methods—: From our prospective intra-arterial therapy database, we identified 107 patients with acute ischemic stroke with anterior circulation proximal artery occlusions who underwent final infarct imaging and had 3-month modified Rankin Scale scores. Clinical, imaging, treatment, and outcome data were analyzed. Results—: Mean age was 66.6 years. Median admission National Institutes of Health Stroke Scale score was 17. Reperfusion (Thrombolysis In Cerebral Infarction 2A–3) was achieved in 78 (72.9%) patients. Twenty-seven (25.2%) patients achieved a 3-month good outcome (modified Rankin Scale 0–2), and 30 (28.0%) died. Median FIV was 71.4 cm 3 . FIV independently correlated with functional outcome across the entire modified Rankin Scale. In receiver operating characteristic analysis, it was the best discriminator of both good outcome (area under the curve=0.857) and mortality (area under the curve=0.772). A FIV of approximately 50 cm 3 demonstrated the greatest accuracy for distinguishing good versus poor outcome, and a FIV of approximately 90 cm 3 was highly specific for a poor outcome. The interaction term between FIV and age was the only independent predictor of good outcome ( P <0.0001). The impact of FIV was accentuated in patients <80 years. Conclusions—: Among patients with anterior circulation acute ischemic stroke who undergo intra-arterial therapy, final infarct volume is a critical determinant of 3-month functional outcome and appears suitable as a surrogate biomarker in proof-of-concept intra-arterial therapy trials.Keywords
This publication has 42 references indexed in Scilit:
- Collateral Flow Predicts Response to Endovascular Therapy for Acute Ischemic StrokeStroke, 2011
- Significance of Large Vessel Intracranial Occlusion Causing Acute Ischemic Stroke and TIAStroke, 2009
- Good clinical outcome after ischemic stroke with successful revascularization is time-dependentNeurology, 2009
- Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen ActivatorStroke, 2009
- Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy TrialsStroke, 2009
- Change in Diffusion-Weighted Imaging Infarct Volume Predicts Neurologic Outcome at 90 DaysStroke, 2009
- MRI-Based Selection for Intra-Arterial Stroke TherapyStroke, 2009
- Expediting MRI-Based Proof-of-Concept Stroke Trials Using an Earlier Imaging End PointStroke, 2009
- Clinical and Imaging Data at 5 Days as a Surrogate for 90-Day Outcome in Ischemic StrokeStroke, 2009
- Revascularization Results in the Interventional Management of Stroke II TrialAmerican Journal of Neuroradiology, 2008